Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Comparative Study Agenda Should Emphasize Lit Reviews – McClellan

Executive Summary

The federal government's investment in comparative effectiveness research for drugs should emphasize literature reviews and other alternatives to clinical trials, Centers for Medicare & Medicaid Services Administrator Mark McClellan said
Advertisement

Related Content

AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
CMS Suggests “Pay For Performance” Approach To Cancer Drug Coverage
Pfizer, Novartis Learning The VALUE Of Comparative Research
Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
AHRQ Outcomes Research Should Focus On Diseases, Not Drugs – PhRMA
AHRQ Outcomes Research Should Focus On Diseases, Not Drugs – PhRMA
Medicare Chronic Care Projects Likely To Meet 5% Savings Goal, Rep. Says
E-Prescribing To Improve Postmarketing Studies, CMS’ McClellan Predicts
FDA Will Be Given Cost-Effectiveness Role, Acting Commissioner Predicts
ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs
Advertisement
UsernamePublicRestriction

Register

PS044054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel